Aktien Sensor

United Therapeutics’ quarterly earnings report showed revenue growth, but the company fell short of analyst expectations, leading to a decline in its stock price.

Mettler-Toledo International Inc. reported a 5% increase in earnings per share in its second-quarter earnings report, exceeding market estimates.

Avantor Inc’s disappointing second-quarter earnings report highlights the challenges facing the chemicals industry, with the company’s stock price taking a hit as it struggles to adapt to a rapidly changing market.

Sanofi’s second-quarter results exceeded market expectations, driven by strong sales of Dupixent and new medicines, with the company’s stock price expected to increase in the coming period.

BioMarin Pharmaceutical Inc. has appointed Ian T. Clark to its Board of Directors, as the company prepares for an upcoming earnings preview amidst a growing THR-β agonist market.

Roche’s Susvimo treatment has achieved a groundbreaking 95% success rate in maintaining vision for patients with age-related macular degeneration over a five-year period.

Ipsen SA has reported strong financial results for the first half of 2025, with a 9.8% increase in sales and a raised annual sales outlook.

Eisai’s Alzheimer’s disease treatment, LEQEMBI, continues to drive growth and innovation, with strong sales and positive clinical data suggesting a potential upward trend in the company’s stock price.

Sartorius Stedim Biotech is a strong buy opportunity, with 80% of analysts recommending a purchase and a potential for growth of over 20%.

Bayer AG’s stock price surged 2.82% on the DAX index, catapulting the company to the top of the index and solidifying its position as a leader in the healthcare industry.